



Antimicrobial Susceptibility Profile (July 1, 2024 through June 30, 2025)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory, Clinics, and Physician Offices.

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

Cefazolin (urine) limited to <i>E. coli</i> , <i>K.pneumoniae</i> and <i>P.mirabilis</i>	Achromobacter xylooxidans		Acin.baumannii complex ^a		Citro. freundii complex ^b		Citrobacter koserii		Klebsiella (Ent) aerogenes ^c		Ent. cloacae complex ^d		Escherichia coli		E. coli (ESBL)		Klebsiella oxytoca		Klebsiella pneumoniae		Kleb pneumo (ESBL)		Klebsiella varicola		Morganella morganii		Proteus hauseri		Proteus mirabilis		Providencia rettgeri		Pseudo aeruginosa		S.marcescens complex ^e	
	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun
Amikacin ^f	*	*			100	100			100	100	100	100	100	100	100	100	100	100	100	100	99	100	100	100		*	*	100	100	100	*	100	100	100	100	
Ampicillin													63	63														89	85							
Ampicillin/Sulbactam			100	98									89	92			90	91	93	95			97	95	14	20	*	*	99	98	74	*				
Cefazolin (urine)													96	96					99	98							99	97								
Cefepime	*	*	96	98	100	100	100	99	100	99	99	97	100	100			100	100	100	100			99	100			*	*	100	100	100	*	98	99	100	100
Ceftazidime																																97	97			
Ceftriaxone	*	*			75	84	100	99	88	89			99	99			97	98	100	100			98	100			*	*	100	99	97	*			97	98
Ciprofloxacin	*	*	100	96	88	97	98	98	98	97			85	83	26	13	99	95	96	97	15	12	98	98	85	90	*	*	96	97	97	*	95	94	97	97
Ertapenem					100	100	100	100	98	100	99	99	100	100	100	100	100	100	100	100	100	100	100	100	100	100	*	*	100	100	100	*			100	100
Gentamicin	*	*			98	99	100	100	99	100	98	97	94	93	70	65	99	100	100	100	71	70	100	100	95	98	*	*	98	97	100	*			100	100
Levofloxacin	*	*			94	100	99	99	99	100	98	96	85	84	18	18	99	100	98	99	18	19	98	100	88	100	*	*	96	100	94	*			98	98
Meropenem			n/a	98	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	n/a	100	*	*	n/a	100	n/a	*	n/a	98	n/a	100
Minocycline			n/a	100																																
Nitrofurantoin (urine)					99	98	98	100	46	43	57	71	99	99	98	98			64	70	27	54														
Piperacillin/Tazobactam ^g	*	*	88	92	n/a	91	99	100	n/a	87			98	98	95	94	n/a	96	96	97	68	73	99	98	97	98	*	*	100	100	92	*				
Tobramycin	*	*	100	98																												100	100			
Trimeth-Sulfa	*	*	97	89	86	88	98	100	97	99	90	93	82	82	42	43	96	63	94	95	16	18	100	100	88	91	*	*	91	90	87	*			99	100
Total Isolates	23	22	105	46	96	67	242	181	176	133	240	151	7113	5797	769	512	78	63	1417	1055	130	76	95	61	156	99	20	8	829	538	38	18	1117	660	107	64
Total # Urine Isolates	3	4	41	12	66	56	198	150	133	103	117	92	4202	5701	716	498	55	42	1252	989	106	63	81	55	81	60	11	7	621	442	23	12	272	185	35	22
												E.coli (ESBL) rate		10%	8%			K.pneumo (ESBL) rate		8%	7%															

Percent susceptible calculations are based on total isolates.

Percent susceptible calculations for drugs specified as "urine" are based on total # urine isolates.

FOOTNOTES:

a *Acinetobacter baumannii* complex includes *A.calcoacecus*, *A.baumannii*, *A.dijkshoomiae*, *A.lactucae*, *A.nosocomialis*, *A.pittii* and *A. seifertii*

b *Citrobacter freundii* complex includes *C.braaki*, *C.freundii*, *C.gillenii*, *C.murliniae*, *C.rodenticum*, *C.sedlakii* and *C.wekmenii*

c *Enterobacter aerogenes* has been renamed *Klebsiella aerogenes*

d *Enterobacter cloacae* complex includes *E.asburiae*, *E.cancerogenus*, *E.cloacae*, *E.dissolvens*, *E.hormaechei*, *E.kobei*, *E.ludwigii* and *E.nimpressuralis*

e *Serratia marcescens* complex includes *S. marcescens*, *S.nemotophila* and *S.ureilytica*

f For urine only with isolates of *Pseudomonas aeruginosa*

g For urine only with isolates of ESBL

<i>Stenotrophomonas maltophilia</i>	Jul-Dec	Jan-Jun
Levofloxacin	93	95
Minocycline	98	94
Trimethoprim/Sulfa	86	90
Total Isolates	63	39
Total # Urine Isolates	16	10

<i>Haemophilus influenzae</i>	Jul-Dec	Jan-Jun
Ampicillin	45	87
Ampicillin/Sulbactam	n/a	97
Azithromycin	100	100
Ceftriaxone	100	97
Ciprofloxacin	n/a	100
Levofloxacin	n/a	100
Meropenem	100	98
Trimethoprim/Sulfa	n/a	60
Total Isolates	52	62
Total # Urine Isolates	2	5

Asterisk (*) indicates no result available

Where isolates in both periods are >=30, the following apply:

Green indicates increase in susceptibility by >5%

Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinically significant and is not provided. These are highlighted in BLUE on these tables.
Source: CLSI Document M39-5thEd, January 2022



Antimicrobial Susceptibility Profile (July 1, 2024 through June 30, 2025)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory, Clinics, and Physician Offices.

GRAM POSITIVE SUSCEPTIBILITIES (Percent Susceptible)

S.aureus complex includes S.aureus, S.argenteus and S.schweitzeri	S. aureus ³ complex MSSA		S. aureus complex MRSA		All S. aureus complex		Staph lugdunensis		All other Staph sp. coag neg		Enterococcus Non-VRE ⁴		Enterococcus faecalis		Enterococcus faecium		Enterococcus VRE		Streptococcus agalactiae		Streptococcus pneumoniae		Streptococcus pyogenes		Streptococcus viridans Group ⁶	
	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun
Ampicillin											98	97	100	100	37	29	*	*	100	100			100	100	99	100
Cefazolin	100	100			73	77	93	84	61	62																
Cefotaxime																										
Ceftriaxone																			100	100			100	100	99	100
Ciprofloxacin (urine)											91	92	93	93	35	*	*	*								
Clindamycin ¹	84	84	69	74	80	82	87	83	64	68									56	52	*	*	90	88		
Daptomycin ²	100	100	100	100	100	100	100	100	100	100																
Erythromycin ¹	77	76	38	39	67	68	89	85	43	44									51	46	*	*	88	87		
Levofloxacin (urine)											n/a	93	n/a	94	*	*	*	*								
Linezolid	100	100	100	100	100	100	100	98	100	100	100	100	100	100	100	100	*	*								
Minocycline ¹	100	100	100	100	100	100	100	100	99	99																
Moxifloxacin																					*	*				
Nitrofurantoin (urine)	100	100	*	*	100	99	*	*	100	100	98	99	100	100	*	*	*	*								
Oxacillin	100	100			73	77	94	82	62	62																
Penicillin	38	39			28	30	48	40	26	25	n/a	97	n/a	99	n/a	29	*	*	100	100			100	100	100	100
Tetracycline ⁵	91	91	75	73	87	87	97	100	77	79	25	28	24	28	37	32	*	*			*	*	n/a	82		
Trimeth-Sulfa	93	94	57	63	84	87	95	98	75	80											*	*				
Vancomycin	100	100	100	100	100	100	100	100	100	100	99	100	100	100	74	74	*	*			*	*			100	100
Total Isolates	2175	1413	782	429	2957	1842	63	45	981	472	1223	868	1149	827	57	34	18	13	127	118	23	14	906	482	93	50
Total # Urine Isolates	121	80	24	20	145	100	29	26	398	336	847	675	813	653	26	23	7	11	10	7	0	0	2	1	29	27
	MRSA Rate		26%	23%											VRE Rate		1%	1%								

Streptococcus pneumoniae								
Cefotaxime			Ceftriaxone			Penicillin		
MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae	
	Jul-Dec	Jan-June		Jul-Dec	Jan-June		Jul-Dec	Jan-June
<=0.12	*	*	<=0.12	*	*	<=0.06	*	*
0.25	*	*	0.25	*	*	0.12	*	*
0.5	*	*	0.5	*	*	0.25	*	*
1	*	*	1	*	*	0.5	*	*
2	*	*	2	*	*	1	*	*
>=4	*	*	>=4	*	*	2	*	*
						4	*	*
						>=8	*	*

S. pneumoniae interpretive guidelines

Penicillin		
Parenteral non-meningitis		
<=2 S	4 I	>=8 R
Parenteral meningitis		
<=0.06 S	----	>=0.12 R
Oral		
<=0.06 S	0.12-1 I	>=2 R
Cefotaxime and Ceftriaxone		
Non-meningitis		
<=1 S	2 I	>=4 R
Meningitis		
<=0.5 S	1 I	>=2 R

Percent susceptible calculations are based on total isolates.
Percent susceptible calculations for drugs specified as "urine" are based on total # urine isolates.

FOOTNOTES:

- ¹ Clindamycin & Erythromycin are not appropriate for urine sources
- ² Daptomycin not reported for lower respiratory tract
- ³ *Staph aureus* (MSSA) isolates that show Penicillin susceptibility may harbor the blaZ gene that produces beta-lactamase.
- ⁴ Non-VRE includes intrinsically resistant *Enterococcus* (*E. casseliflavus* & *E.gallinarum*)
- ⁵ For urine only with isolates of *Enterococcus*
- ⁶ *Viridans Strep* Group includes *S.anginosus* group, *S.bovis* group, *S.mitis* group, *S.mutans* group, *S.salivarius* group, and *S.sanguinis* group

Asterisk (*) indicates no result available

Where isolates in both periods are >=30, the following apply:

Green indicates increase in susceptibility by >5%

Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinically significant and is not provided. These are highlighted in BLUE on these tables.

Source: CLSI Document M39-5thEd, January 2022